Two years of eGFR data are now the center of a regulatory conversation that Vera Therapeutics did not expect to be having this soon. On September 15, 2026, the company announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of ORIGIN 3, the Phase 3 trial in 428 adults with primary IgA nephropathy at risk for disease progression. The drug already holds accelerated FDA approval for proteinuria reduction, granted in July 2026 on the strength of an interim read from the same trial. What the final analysis adds is stabilized eGFR and prevention of kidney disease progression through 104 weeks, the kind of functional outcome that accelerated approvals are designed to eventually require.
That distinction matters for how this data package moves through the regulatory system. Accelerated approval is conditional: sponsors must confirm clinical benefit in a post-approval study, and the FDA can withdraw approval if that confirmation never arrives or arrives weakly. The ORIGIN 3 final analysis is effectively that confirmatory dataset, and hitting every prespecified endpoint in 428 patients over two years removes the largest near-term risk to TRUTAKNA’s commercial position. Vera filed an 8-K disclosing the results the same day and noted it updated its corporate presentation in connection with the release.
For trial-operations teams and site investigators, the two-year duration of ORIGIN 3 is worth noting. IgAN trials historically struggled to capture eGFR slope changes in shorter windows; a 104-week endpoint that holds across all prespecified measures gives regulators a cleaner signal than proteinuria alone. The interim analysis in the New England Journal of Medicine built the accelerated-approval case; this final read is what converts a provisional label into a durable one.
The immediate marker to watch is whether Vera submits a supplemental BLA or a label-update filing and how quickly FDA moves it through, since the confirmatory data package is now in hand.
Source link: https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
